Needham Reiterates Buy on Pliant Therapeutics, Maintains $38 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer reiterates a Buy rating on Pliant Therapeutics (NASDAQ:PLRX) and maintains a $38 price target.
July 16, 2024 | 5:25 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Joseph Stringer reiterates a Buy rating on Pliant Therapeutics and maintains a $38 price target.
The reiteration of a Buy rating and the maintenance of a $38 price target by a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100